AbbVie is acquiring Apogee Therapeutics for $10.9 billion to strengthen its immunology portfolio and prepare for upcoming patent expirations. AbbVie's existing drugs Skyrizi and Rinvoq have already surpassed Humira's peak sales and continue growing rapidly. Apogee's lead drug candidate, Zumilokibart, shows promising efficacy for atopic dermatitis, with Phase 3 trial results expected in 2028 and potential approval by 2030. The current valuation of AbbVie does not yet reflect Apogee's pipeline, offering investors potential upside as new data and approvals approach.
In June 2026, biotechnology ETFs dominated the top performers, driven by AI advancements and increased mergers and acquisitions, with ARKG leading at a 24.15% return. Passive biotech ETFs like BBC, SBIO, and XBI also saw strong gains. Meanwhile, the ...
A bipartisan US congressional committee is investigating whether Merck, AbbVie, and three other major pharmaceutical companies conducted clinical trials in China that may have supported Chinese military capabilities. The inquiry focuses on due dilige...
US equity markets show signs of speculative excess with record margin debt at $1.4 trillion and leveraged ETF assets at $198 billion. The tech-heavy Nasdaq experienced its largest weekly drop since April 2025, reflecting a pullback in the most specul...
AbbVie announced positive topline results from the Phase 3 EPCORE DLBCL-4 trial, where epcoritamab combined with lenalidomide significantly improved progression-free survival in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBC...
A new study analyzing nearly 68,000 US patients found that adoption of adalimumab biosimilars increased significantly after formulary changes, but over 16% of those who switched from Humira reverted back to the original drug. The research highlights ...
